Latest Diabetes mellitus type 1 Stories

A rare genetic disorder has given researchers at the University of Exeter a surprising insight into how the pancreas develops. The finding provides a clue to how it may be possible to 'program' stem cells – master cells in the body that can develop into specialized cells – to become pancreatic cells. Pancreatic agenesis is a rare condition in which the body is unable to produce a pancreas. The pancreas plays an essential role in regulating levels of sugar (glucose) in the blood. It...

DENVER, Dec. 8, 2011 /PRNewswire/ -- Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTC OMBP.OB) today announced that U.S. Patent No. 8,071,551, entitled "METHODS AND COMPOSITIONS FOR TREATING DIABETES," was issued by the United States Patent and Trademark Office on December 6, 2011 (the "Diabetes Patent"). The Diabetes Patent expires in May 2022. The Diabetes Patent is the most recently issued patent that Omni Bio licenses under agreements with the University of Colorado Denver and...

WORCESTER, Mass. and TORONTO, Dec. 7, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today that a group of physicians led by Professor Paolo Pozzilli at the University Campus Bio-Medico in Rome, Italy, will provide an update on results of using Generex Oral-lyn(TM) as it pertains to prediabetes at the forthcoming International Diabetes Federation (IDF) Congress, to be held in Dubai, December 3(rd)-8(th), 2011. (Logo:...

WORCESTER, Mass., Dec. 5, 2011 /PRNewswire/ -- Grove Instruments, Inc., a medical device company based in Worcester, MA, developing the world's first noninvasive glucometer today announced that Craig Mello, Ph.D. is joining the Board of Directors. Dr. Mello is a Howard Hughes Medical Institute Investigator and the Blais University Chair of Molecular Medicine and Co-Director of the RNA Therapeutics Institute at the University of Massachusetts School of Medicine. Dr. Mello's...

Technique should help research into pre-clinical and clinical evaluation of cells Scientists in Canada have overcome a key research hurdle to developing regenerative treatments for diabetes and liver disease with a technique to produce medically useful amounts of endoderm cells from human pluripotent stem cells. The research, published in Biotechnology and Bioengineering, can be transferred to other areas of stem cell research helping scientists to navigate the route to clinical use known...

Cellular movies could greatly enhance search for Type 1 disease interventions A war is being waged in the pancreases of millions of people throughout the world. The siege leads to the development of type 1 diabetes and has been a battlefield largely hidden from view-- until now. Researchers at the La Jolla Institute for Allergy & Immunology have created the first cellular movies showing the destruction underlying type 1 diabetes in real-time in mouse models. This detailed, dynamic view...

FDA's Draft Guidance Is A First Step to Providing Access to Life-Saving Technology for Millions with Type 1 Diabetes WASHINGTON, Dec. 1, 2011 /PRNewswire-USNewswire/ -- The JDRF today said it is encouraged that the Food and Drug Administration (FDA) has issued a draft guidance which appears to lay a foundation for accelerating the development and availability of artificial pancreas technology (AP) that will improve the lives of millions of Americans living with type 1 diabetes...

Agency provides options for device designs and studies SILVER SPRING, Md., Dec. 1, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today issued draft guidance designed to help investigators and manufacturers as they develop and seek approval for artificial pancreas device systems to treat type 1 diabetes. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) To facilitate development of this novel product in an evolving area, the draft guidance provides flexible...

WORCESTER, Mass. and TORONTO, Dec. 1, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today provided an update on the status of the clinical and regulatory program for Generex Oral-lyn(TM), the Company's proprietary buccal insulin spray product. Work has been completed on reviewing, validating, re-analyzing (including additional new analyses), and revising all of the extant Generex Oral-lyn(TM) Clinical Study Reports. In addition, the data...

PRINCETON, N.J. and INDIANAPOLIS, Ind., Nov. 15, 2011 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and Chip Ganassi Racing Teams, Inc. announced today that the two organizations have entered into a multi-year extension of their partnership. Novo Nordisk will remain the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the IZOD IndyCar Series. To view the multimedia assets associated with this release, please click:...